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Continuous manufacturing has gained a lot of attention over the last 10-15 years for numerous reasons such as 
the potential for higher efficiencies, reduced cost of goods, and improved product quality. However, the adoption 
of these technologies has been slow due to concerns over operating these processes in a GMP manufacturing 
environment. Some of these concerns relate to the operation of multiple continuous unit operations in an 
integrated process sequence. This presentation will highlight these concerns and show how these issues were 
addressed by developing an overarching automated and modular platform which can be easily adapted for 
processing most products.  
 
The developed automation platform is the result of a project funded by Innovate UK that brings together a 
number of biopharmaceutical companies including Allergan, AstraZeneca, Fujifilm Diosynth Biotechnologies and 
GSK to identify and address these issues. One objective of the project is to develop a flexible automated 
biologics downstream process consisting of multiple unit operations that can be rapidly reconfigured for 
manufacturing different products. To that end the process has been design with modularity in mind with each 
module having common inputs and outputs. The automation software has also been developed in a way that 
most typical downstream processes can be implemented in the system with little to no software updates. The 
ability to rapidly reconfigure the process has been demonstrated by using the system to produce two products 
with different process sequences.  
 
Another issue that inhibits the adoption of continuous technologies is the concern over simultaneously operating 
multiple unit operations. This presentation will detail how the automation software was developed to control both 
the key unit operations such as chromatography and filtration steps but also intermediate operations such as 
feed conditioning and viral inactivation steps. The automated system reduces the complexity of downstream 
processes, which can have in excess of eleven unit operations, to a single user-friendly interface. Implementing 
this control platform enables a single operator to control the entire process.  
 
This presentation will also detail how the automation strategy has been developed to enable a single operator to 
deal with start-up/shutdown, perturbations in the process and mid-process equipment turnover. It will highlight 
the challenges that have been faced when developing this system and how these have been overcome.  
The aim of this project was to improve efficiency by reducing processing time when compared to the current 
batch process and this was demonstrated by testing the system with two different products (a MAb and a MAb 
fusion protein). Furthermore, this presentation with show data from the production of these two products that 
demonstrates comparability between the continuous process and the original batch processes.  
 
 
 
 
 
 
 
 
